Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The lymphomas.

V T DeVita1, G P Canellos

  • 1Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.

Seminars in Hematology
|December 14, 1999
PubMed
Summary
This summary is machine-generated.

Therapeutic advances in lymphomas, including Hodgkin's disease and diffuse large B-cell lymphomas, have established cancer treatment paradigms. Current research leverages immune system biology to identify new targets for lymphoma therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Primary treatment of Hodgkin's disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

Cancer·2001
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Review of historical therapeutic strategies for lymphomas.
  • Establishment of treatment paradigms through curative approaches for Hodgkin's disease and diffuse large B-cell lymphomas.
  • Foundation for broader cancer treatment strategies.

Observation:

  • Significant progress in understanding lymphoma biology.
  • Elucidation of the immune system's role in lymphoma origins.
  • Identification of specific molecular targets.

Findings:

  • Historical treatments for lymphomas created successful cancer therapy models.
  • Advances in immunology have revealed the cellular origins of lymphoma subtypes.
  • New therapeutic targets are emerging from a deeper understanding of immune system interactions.

Related Experiment Videos

Implications:

  • Potential for novel, targeted therapies in lymphoma treatment.
  • Translational research bridging immunology and oncology.
  • Improved patient outcomes through precision medicine approaches in hematologic malignancies.